15 October 2015 - Baxalta today announced that Health Canada has approved Obizur [anti-haemophilic factor (recombinant), porcine sequence] for the treatment of bleeding episodes in patients with acquired haemophilia A caused by auto-antibodies to coagulation factor VIII, a very rare and life-threatening acute bleeding disorder.

For more details, go to: http://newsroom.baxalta.com/press-releases/press-release-details/2015/Baxalta-Gains-Health-Canada-Approval-for-OBIZUR-to-Treat-Patients-with-Acquired-Hemophilia-A/default.aspx

MAESTrO Insight: the generic name for this technology is susoctacog alfa.